# Stephen Thompson

> Stephen Thompson is a Series A investor at Brandon Capital backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners)
- Location: Melbourne, Australia
- Total investments: 8
- Last investment: Feb 2026
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/stephen-thompson-a27349149
- Website: https://brandoncapital.vc/team_member/stephen-thompson/

Stephen Thompson is a founding Partner of Brandon Capital Partners. Previously Stephen worked with Bio Innovation SA and helped establish Terra Rossa Capital, a dedicated life science Fund Manager in Adelaide. Prior to this Stephen was a Director of Apax Partners a leading international private equity group based in London. During thistime Stephen was also a Director of Imperial Innovations, the commercialisation company of Imperial College London. Before joining Apax Partners, Stephen fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California. Stephen is a Member of the Board of Directors at Elastagen P/L, MiReven P/L, Vaxxas P/L, Helmedix P/L, Auspherix P/L and Council Member of the Australian Venture Capital Association Limited (AVCAL). Stephen has an Honours degree in Immunology and Biochemistry, a Ph.D. in Immunology from Kings College London and an MBA, specialising in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors and a Member of AusBiotech.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Health Care | 3 | 38% |
| Medical Device | 2 | 25% |
| Medical | 1 | 13% |
| Software | 1 | 13% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Seed | 2 | 25% |
| Series D | 1 | 13% |
| Funding Round | 1 | 13% |
| Venture - Series Unknown | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Australia | 3 | 38% |
| United States | 1 | 13% |
| United Kingdom | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OncoRes Medical | OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure. | $19.2M | Venture - Series Unknown | Feb 12, 2026 |  |
| Vaxxas | Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $31.8M | Series D | Aug 25, 2025 |  |
| Myricx Bio | Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases. | $115.3M | Series A | Jul 08, 2024 |  |
| OncoRes Medical | OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure. | $6.6M | Series A | May 18, 2022 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $5.5M | Seed | Nov 19, 2018 |  |
| Vaxxas | Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $10.1M | Series A | Aug 02, 2011 |  |
| Myricx Bio | Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases. | $5.9M | Seed |  |  |
| Longas | Longas Technologies, a Next Generation Sequencing (NGS) technology developer, has provided details on its Morphoseq™ library prep and associated software technology at the ‘Sequencing, Finishing and Analysis. |  |  |  |  |

8 of 8 investments shown.

## Co-investors
- [OneVentures](https://shizune.co/investors/profile/one-ventures) — VC Fund, 2 deals together
- [Radar Ventures](https://shizune.co/investors/profile/radar-ventures) — VC Fund, 2 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 1 deal together
- [Future of Healthcare Fund - Australian Unity](https://shizune.co/investors/profile/australian-unity-s-future-of-healthcare-fund) — VC Fund, 1 deal together

## About Brandon Capital

VC Fund · Melbourne, Australia

Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.

5 contacts available at Brandon Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Chris Nave | Partner, Managing Director & Co-Founder | https://shizune.co/investors/profile/chris-nave |
| Robert Daniels | Venture Partner | https://shizune.co/investors/profile/robert-daniels |
| Stephen Thompson | Partner | https://shizune.co/investors/profile/stehpen-thompson |
| Bob Soh | Senior Investment Manager | https://shizune.co/investors/profile/bob-soh |
| Darren Kelly | Entrepreneur in Residence | https://shizune.co/investors/profile/darren-kelly-d974 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Stephen Thompson invest in?

Stephen Thompson invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Stephen Thompson last invest?

The most recent investment recorded for Stephen Thompson closed in Feb 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co